The Centers for Medicare and Medicaid Services (CMS) has announced a sweeping policy change that will end all federal Medicaid and Children’s Health Insurance Program (CHIP) funding for puberty blockers, cross-sex hormones, and surgical procedures for minors. The decision, made official through a final rule issued this week, represents a significant shift in federal health policy regarding pediatric gender-related medical interventions.
Explainer The Evolving Landscape of American Health Care Legislation
CMS and the Department of Health and Human Services (HHS) cited safety concerns and insufficient evidence as the primary reasons for the change. According to a CMS press release, the decision follows a comprehensive review by HHS. The review found "evidence gaps, documented serious safety concerns, and concluded that the evidence supporting these interventions for children remains insufficient to justify federal taxpayer funding." The agency referenced national and international research, including the United Kingdom’s Cass Report, as influential in its reassessment of these treatments.
Details of the Final Rule
Under the new rule, federal reimbursement for what CMS terms "sex-rejecting procedures on children"—including puberty blockers, cross-sex hormones, and surgical operations—will be discontinued. CMS Administrator Dr. Mehmet Oz emphasized that the rule has the force of law and described the interventions as carrying "serious long-term health risks," such as infertility, impaired sexual function, diminished bone density, and altered brain development.
"By cutting off federal funds for these sex-rejecting procedures, we’re following the science, saving taxpayer dollars, and, most importantly, protecting children from potentially irreversible harm so they can truly flourish."
— Dr. Mehmet Oz, CMS Administrator
HHS Secretary Robert F. Kennedy, Jr. echoed these concerns, stating, "These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve."
The final rule includes a six-month “tapering-off period” for minors who are already receiving these medications. This period is intended to allow for a transition and minimize potential disruption in care. The rule does not affect Medicaid or CHIP coverage for mental health services, which will continue to be available for children experiencing gender dysphoria or related concerns.
Federal and Political Reactions
The CMS decision has drawn strong reactions from political leaders and advocacy groups. President Donald Trump praised the move, stating on social media, "Medicaid will NO LONGER fund gender transition surgeries or hormones for minors. We are not going to pay for our innocent children to undergo these barbaric surgeries and practices, which result in unthinkable and irreversible harm to their young bodies."
Terry Schilling, president of the American Principles Project, described the policy as overdue. "No hardworking American should be forced to bankroll irreversible hormones and surgeries that carve up healthy young bodies under the banner of a radical ideology," Schilling said.
The CMS decision comes at a time of ongoing debate within the medical community and among policymakers. The agency noted that some professional organizations, such as the American Society of Plastic Surgeons, are currently clarifying their positions on these interventions. CMS also referenced international reviews and policy changes, including those in the United Kingdom following the Cass Report, which have led to more restrictive approaches to pediatric gender treatments in some countries.
Medical Community and Ongoing Debate
The medical community remains divided on the issue. The World Professional Association for Transgender Health (WPATH), which has authored standards of care for gender-related treatments, has recently stated in court that its guidelines represent "one side of an unsettled medical debate" and are "opinions" within the realm of "medical and scientific uncertainty."
Supporters of gender-affirming care for minors have not issued a formal response to the CMS rule as of publication. However, the rule’s implementation is expected to have significant implications for access to care for transgender and gender-diverse youth who rely on Medicaid or CHIP for medical services.
It is important to note that the new CMS rule does not alter Medicaid or CHIP coverage for mental health services related to gender dysphoria. These services will remain available to eligible minors, even as coverage for medical interventions is phased out.
The CMS rule is now in effect, with a six-month transition period for those currently receiving affected treatments. After this period, federal funding for puberty blockers, cross-sex hormones, and surgical procedures for minors under Medicaid and CHIP will cease. The agency has stated that it will monitor the implementation of the rule and continue to review emerging evidence regarding pediatric gender-related medical care.
The policy change marks a notable development in the ongoing national conversation about the role of government funding in pediatric gender medicine, and is likely to prompt further debate and potential legal challenges as states and providers adjust to the new federal requirements.
